<?xml version="1.0" encoding="UTF-8"?>
<p id="Par12">In conclusion, the data here reported indicate the Sofosbuvir as the lead compound with the highest potential of antiviral efficacy in SARS-CoV-2 infection. In addition, the long-lasting use in patients for treating and eradicating HCV chronic infection provides also the full knowledge of its safety profile [
 <xref ref-type="bibr" rid="CR13">13</xref>]. If the evaluation in humans will hold the premises of the in silico analyses, Sofosbuvir will become an extraordinary therapeutic tool to inhibit the SARS-CoV-2 replication and, ultimately,Â to make the current pandemic a manageable disease.
</p>
